CyanoCapture and Persist AI Join Forces to Innovate Oral Drug Production with Robotics

Innovation in Oral Drug Manufacturing

In a significant leap towards improving drug delivery methods, CyanoCapture and Persist AI have teamed up to create the world’s first robotic Good Manufacturing Practice (GMP) facility dedicated to the production of oral protein and peptide drugs. This pioneering facility is set to revolutionize the pharmaceutical landscape by offering a scalable, efficient solution for delivering life-saving biologics directly to patients. The facility is anticipated to commence operations in the fourth quarter of 2026, and will be based in the San Francisco Bay Area.

Addressing Challenges in Drug Delivery

The partnership aims to tackle a long-standing challenge in the pharmaceutical industry: the transition from injectable biologics to oral alternatives. CyanoCapture utilizes a unique platform that harnesses the potential of cyanobacteria, specifically engineered to produce biologics encapsulated within protein nanocages called carboxysomes. This innovative approach not only has the potential to streamline drug delivery but also to eliminate the discomfort of daily injections that affect millions of patients globally.

Cyanobacteria, a class of bacteria naturally occurring in various environments, have become increasingly recognized for their health benefits. They are rich in bioactive compounds and can be engineered to yield significant quantities of therapeutic peptides and proteins. CyanoCapture’s process involves reprogramming the DNA of these photosynthetic cells, enabling them to produce the desired compounds according to specific designs.

The Role of AI in Production

The cutting-edge facility will utilize Persist AI's advanced robotic systems to maximize productivity in formulation development and clinical materials production. AI technologies will be integral to the operations, enhancing scheduling, tracking workflows, and optimizing processes throughout the entire manufacturing pipeline. According to David Kim, CEO of CyanoCapture, the collaboration with Persist AI integrates the precision of robotics with the innovative oral delivery platform provided by CyanoCapture, ultimately enabling faster transitions from lab research to patient usage.

Persist AI’s automation capabilities will not only accelerate drug development timelines but will redefine the manufacturing landscape for biologics. Their cloud-based laboratory already demonstrates efficiencies up to thirty times faster than conventional methods. Karthik Raman, CEO of Persist AI, emphasizes that this partnership will not only speed up the development process but will also allow for precise, high-quality drug production that can meet the needs of patients who require alternatives to traditional injection methods.

A New Era for Therapeutic Drug Production

This collaboration shines a light on the future of therapeutic drug production, with plans to address the emerging needs in patient-care delivery by focusing on the conversion of injectable therapeutics into oral formulations. The new robotic GMP facility is not just about speeding up existing processes, but about reimagining how biologics are manufactured in a way that aligns with modern patient needs and expectations.

As the pharmaceutical industry continues to seek innovative strategies to enhance drug efficacy and delivery, collaborations like that of CyanoCapture and Persist AI underscore a transformative shift towards personalized, patient-friendly therapeutic options. Supported by venture firms such as Cartography Ventures, this unique ecosystem is designed to foster innovation and lead to breakthroughs that could reshape the future of healthcare.

In conclusion, the strategic collaboration between CyanoCapture and Persist AI holds the promise of providing new, effective delivery methods for biologics that could potentially change the lives of countless patients worldwide. With both companies at the forefront of their respective fields—biotechnology and AI robotics—the foundation is set for a future where oral biologics become a standard, accessible treatment option.